RiverPark Advisors LLC Invests $233,000 in GeneDx Holdings Corp. (NASDAQ:WGS)

RiverPark Advisors LLC bought a new stake in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 3,031 shares of the company's stock, valued at approximately $233,000.

A number of other large investors have also recently bought and sold shares of the company. MCF Advisors LLC increased its holdings in GeneDx by 107.7% in the fourth quarter. MCF Advisors LLC now owns 351 shares of the company's stock valued at $27,000 after buying an additional 182 shares in the last quarter. Sterling Capital Management LLC increased its holdings in GeneDx by 877.8% in the fourth quarter. Sterling Capital Management LLC now owns 352 shares of the company's stock valued at $27,000 after buying an additional 316 shares in the last quarter. Global Retirement Partners LLC purchased a new position in GeneDx in the fourth quarter valued at $28,000. MetLife Investment Management LLC increased its stake in shares of GeneDx by 6.2% during the fourth quarter. MetLife Investment Management LLC now owns 7,750 shares of the company's stock worth $596,000 after purchasing an additional 453 shares in the last quarter. Finally, Rhumbline Advisers increased its stake in shares of GeneDx by 5.5% during the fourth quarter. Rhumbline Advisers now owns 19,750 shares of the company's stock worth $1,518,000 after purchasing an additional 1,021 shares in the last quarter. Hedge funds and other institutional investors own 61.72% of the company's stock.

GeneDx Trading Up 2.2 %

Shares of WGS stock traded up $2.45 on Tuesday, hitting $114.94. The stock had a trading volume of 345,383 shares, compared to its average volume of 700,824. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The firm has a market capitalization of $3.23 billion, a P/E ratio of -58.84 and a beta of 1.93. GeneDx Holdings Corp. has a 1 year low of $10.70 and a 1 year high of $116.24. The company's 50 day moving average price is $95.80 and its 200-day moving average price is $82.37.

GeneDx (NASDAQ:WGS - Get Free Report) last issued its earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.66. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. The firm had revenue of $95.64 million for the quarter, compared to analysts' expectations of $82.24 million. Analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. TD Cowen boosted their target price on shares of GeneDx from $75.00 to $118.00 and gave the stock a "buy" rating in a research note on Tuesday, January 7th. The Goldman Sachs Group boosted their target price on shares of GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 19th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $72.33.

Insider Transactions at GeneDx

In other GeneDx news, CFO Kevin Feeley sold 402 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $90.05, for a total transaction of $36,200.10. Following the completion of the sale, the chief financial officer now directly owns 5,044 shares of the company's stock, valued at $454,212.20. This represents a 7.38 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Katherine Stueland sold 46,594 shares of the company's stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $89.62, for a total value of $4,175,754.28. Following the sale, the chief executive officer now directly owns 1,720 shares of the company's stock, valued at approximately $154,146.40. This represents a 96.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 138,780 shares of company stock valued at $12,907,437. Insiders own 27.30% of the company's stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.